Company Address:
Manhattan Scientifics
The Chrysler Bldg.
32nd Floor
405 Lexington Ave.
New York, N.Y.
10174
USA
 Phone:
(212) 551-0577
 Website:
www.mhtx.com
 Ticker:
MHTX
 Exchange:
OTC BB
FREE E-MAIL ALERTS

  • ABOUT HAWK
  • HAWK CLIENTS
  • HAWK SERVICES
  • CONTACT HAWK
The Chrysler Bldg. • 32nd Floor • 405 Lexington Ave. • New York • N.Y. • 10174 • USA • www.mhtx.com
Investor Contact: Frank N. Hawkins, Jr. or Julie Marshall · Hawk Associates Inc. · (305) 451-1888 · www.hawkassociates.com
Manhattan Scientifics Reports First Ever Profitable Quarter
Since its inception Manhattan Scientifics Inc. has been a technology developer that nurtures financially promising technologies with potential global commercial applications. The company and its affiliates now own a significant IP portfolio and patents in alternative energy, hydrogen fuel cells and computer 3D touch haptics.

The company’s business model is to commercialize, bringing products to market to create profit for its shareholders through partnerships with manufacturers and licensees of its patents.

Manhattan Scientifics has enjoyed a “special informal relationship" and a successful history in tech-transfer from the Los Alamos National Laboratory (LANL) and the Sandia National Laboratory (SNL).

An example of this relationship was the seed funding and launch of Novint Technologies, which acquired the exclusive, perpetual, global license to the Haptics touch technology from Sandia National Labs and now trades as a listed company in the Over-the-Counter Bulletin Board under ticker symbol NVNT. For more information, visit http://www.novint.com.


Differentiators

NanoTitanium

Manhattan Scientifics owns exclusive rights to the key patents and IP portfolio to produce and market NanoTitanium and other ultra fine grain nano-structured metals. The company acquired Metallicum together with its patent rights for new ultra fine grain metals that may advance the medical device industry, particularly for dental implants, cardiovascular stents and for a wide range of prosthetic applications including artificial knees, shoulders, and hips. NanoTitanium is highly compatible with bone and is thought to provide stronger, faster bonding with improved strength, biocompatibility, longer life and improved wear and tear. To date more than $12 million has been directed toward developing the process. Dr. Lowe has been dubbed one of LANL’S “technology commercialization all-stars.”

Alternative Energy Technologies

Manhattan Scientifics is pursuing several potential solutions to the global alternative energy need as it relates to personal, 2-wheel transportation, particularly in Asia. The company won Time Magazine’s “Invention of the Year” award for its fuel cell Aprilia concept bicycle/fuel cell engine in 2001. MHTX owns the patents and IP technology for the award winning NovArs hydrogen powered fuel cell engine. Light weight and portable, it may be ideal to provide an inexpensive and environmentally friendly "green" system to drive scooters, bicycles, power tools, portable electronics, wheel chairs, golf carts and home emergency power.

MicroFuel Cell

Manhattan Scientifics provided seed funding for former Los Alamos National Laboratory scientist Robert Hockaday, who is developing a flat printed fuel cell designed to provide an “always on” energy source to power micro-electronics such as cellular telephones and pagers. Manhattan Scientifics owns the worldwide right to the patented technology. To date, the micro fuel cell has not been commercialized.

Haptics

Manhattan Scientifics provided $4.5 million seed funding to launch Novint Technologies Inc. The patented Novint Falcon, a computer game controller, enables the ability to touch and realistically feel images on a computer screen including texture, weight, motion and viscosity. The company is gaining recognition and growing rapidly, recently signing an agreement with EA games, whereby the company will create games compatible with the controller.

TECHNOLOGY AND BACKGROUND

Manhattan Scientifics began as a technology incubator. Early in its history it worked on acquiring several technologies in the fields of holographic data storage, water purification, alternative energy, advanced computer haptics and most recently, nanotechnology. The majority of MHTX’s commercial technologies come from U.S. government laboratories in New Mexico. During 2000, Manhattan Scientifics had a market capitalization approaching $900 million, about 60 times the company's present market cap, despite the fact that the company’s intrinsic value is worth many times more today than it was in year 2000.

Scientific Advisory Board

Dr. Terry Lowe – previously served as deputy director of the Materials Science and Technology division.

Dr. Arthur Kaufman,Previously Co-founder and Chief Scientist of H-Power.

Dr. Arthur Koschany – Mid-Range Fuel Cell Scientist, Passau, Germany.

Dr. Martin Cooper – 28 years chief technical officer with Motorola. “Father” of the cellular telephone.

Donald J. Sandstrom – 42 years with LANL. Materials Science Technology Division Leader.

Dr. Henry Rack – received his B.S., M.S. and Sc.D in Metallurgy from MIT. Recent News
Manhattan Scientifics and Dr. Edward R. Flynn featured in Article on Novel Early Cancer Detection and Treatment
Manhattan Scientifics Reports First-Ever Profitable Quarter
Manhattan Scientifics and Senior Scientifics Collaborate to Enhance Early Cancer Detection System
Manhattan Scientifics, Inc. Announces Exclusive License with Carpenter Technology Corporation
Manhattan Scientifics' CEO, Manny Tsoupanarias Issues A Letter To MHTX Shareholders

    Risk Factors
  • Access to sufficient capital to bring product to market; to defend its patents; to surpass its competitors
  • No significant revenue or earnings
  • Ability to recruit additional senior management
  • Potential technical obsolescence
  • Numerous well-capitalized competitors

The Outlook MHTX continues its role as pioneer in the fields of alternative energy and advanced computing, as the company looks to expand its reach in 2008 into new markets including NanoTitanium.

MHTX found it difficult to generate profit through its licensing business model. Accordingly, the company switched its business model to an emerging technology commercialization platform and is diligently seeking manufacturing partners in Asia. Management remains focused on turning the company around, finding capital and reinventing itself as a high value-add commercialization platform across multiple sectors.

In Feb., MHTX completed $1.0 M equity raise for general-purpose working capital. In May, MHTX was fully reporting and applied for Listing on OTCBB.

Management
CEO, President and Chairman-
Emmanuel Tsoupanarias

Non-Executive Chairman of Manhattan Scientifics, a member of the Board of Directors of Novint Technologies, Inc.-
Marvin Maslow

Director-
Leonard Friedman

Director-
Frank Georgiou

Director-
Chris Theoharis

Back To Top